[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602006016127D1 - Zusammensetzung und dosierform mit einer festen oder halbfesten matrix - Google Patents

Zusammensetzung und dosierform mit einer festen oder halbfesten matrix

Info

Publication number
DE602006016127D1
DE602006016127D1 DE602006016127T DE602006016127T DE602006016127D1 DE 602006016127 D1 DE602006016127 D1 DE 602006016127D1 DE 602006016127 T DE602006016127 T DE 602006016127T DE 602006016127 T DE602006016127 T DE 602006016127T DE 602006016127 D1 DE602006016127 D1 DE 602006016127D1
Authority
DE
Germany
Prior art keywords
matrix
solid
composition
dosage form
resistant matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016127T
Other languages
English (en)
Inventor
Joerg Rosenberg
Markus Maegerlein
Joerg Breitenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of DE602006016127D1 publication Critical patent/DE602006016127D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602006016127T 2005-07-05 2006-06-22 Zusammensetzung und dosierform mit einer festen oder halbfesten matrix Active DE602006016127D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59543505P 2005-07-05 2005-07-05
EP05014555 2005-07-05
PCT/EP2006/006026 WO2007003278A1 (en) 2005-07-05 2006-06-22 Composition and dosage form comprising a solid or semi-solid matrix

Publications (1)

Publication Number Publication Date
DE602006016127D1 true DE602006016127D1 (de) 2010-09-23

Family

ID=34981748

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016127T Active DE602006016127D1 (de) 2005-07-05 2006-06-22 Zusammensetzung und dosierform mit einer festen oder halbfesten matrix

Country Status (9)

Country Link
US (1) US20090220596A1 (de)
EP (1) EP1898954B1 (de)
JP (1) JP5232644B2 (de)
CN (1) CN101217981A (de)
AT (1) ATE476997T1 (de)
CA (1) CA2612864A1 (de)
DE (1) DE602006016127D1 (de)
RU (1) RU2423997C9 (de)
WO (1) WO2007003278A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
MX2010002409A (es) * 2007-09-03 2010-05-19 Nanotherapeutics Inc Composiciones y metodos para la distribucion de farmacos escasamente solubles.
EP2072044A1 (de) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmazeutische Dosierungsform mit einer Flüssigkeits- oder Flüssigkern-Zusammensetzung
EP2140861A1 (de) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmazeutische Dosierungsform mit polymerischer Trägerzusammensetzung
WO2010017053A1 (en) * 2008-08-06 2010-02-11 Isp Investments, Inc. Solid excipient compositions
KR101456741B1 (ko) * 2008-09-18 2014-10-31 퍼듀 퍼머 엘피 폴리(e-카프로락톤)을 포함하는 제약 투여 형태
EP2654731B1 (de) * 2010-12-23 2016-07-27 AbbVie Deutschland GmbH & Co. KG Feste verzögerungsformulierungen basierend auf festdispergierungen
RU2471491C1 (ru) * 2011-10-19 2013-01-10 Станислав Анатольевич Кедик Применение сополимера на основе n-винилпирролидона в качестве средства, потенцирующего анальгетический эффект морфина гидрохлорида
JP6218664B2 (ja) * 2013-04-04 2017-10-25 沢井製薬株式会社 テルミサルタン含有錠剤
RU2586290C1 (ru) * 2014-12-18 2016-06-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
IL307454A (en) 2021-04-07 2023-12-01 Battelle Memorial Institute Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
TW474824B (en) * 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
DE19641436A1 (de) 1996-10-08 1998-04-09 Basf Ag Komplexe aus Wasserstoffperoxid und 1,3-Bis-(N-lactamyl)propan
DE19641437A1 (de) * 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19842914A1 (de) * 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs

Also Published As

Publication number Publication date
WO2007003278A1 (en) 2007-01-11
JP5232644B2 (ja) 2013-07-10
RU2008103482A (ru) 2009-08-10
RU2423997C2 (ru) 2011-07-20
JP2009500301A (ja) 2009-01-08
CA2612864A1 (en) 2007-01-11
ATE476997T1 (de) 2010-08-15
EP1898954A1 (de) 2008-03-19
US20090220596A1 (en) 2009-09-03
RU2423997C9 (ru) 2011-11-20
CN101217981A (zh) 2008-07-09
EP1898954B1 (de) 2010-08-11

Similar Documents

Publication Publication Date Title
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
BRPI0606121A2 (pt) composição farmacêutica, processo de manufaturar a mesma, e, uso de uma composição farmacêutica
BRPI0413361B8 (pt) comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
HRP20151202T1 (hr) Oralna formulacija metadoksina
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
AT510866A3 (de) Stabiles pharmazeutisches kombinationspräparat
ATE442864T1 (de) Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
CU20070094A7 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
WO2008015232A8 (en) Subcutaneous implants releasing an active principle over an extended period of time
BRPI0608395A2 (pt) composição farmacêutica sólida que compreende telitromicina
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
SE0000303D0 (sv) Novel compounds
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions